Trial Profile
A Multicenter, Randomized, Double-blind, Placebo-controlled Study of Darbepoetin Alfa for the Treatment of Anemia of Cancer.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Darbepoetin alfa (Primary)
- Indications Anaemia
- Focus Therapeutic Use
- Sponsors Amgen
- 05 Nov 2010 New trial record.
- 16 Nov 2006 Planned patient number is 1000 according to ClinicalTrials.gov (Parent trial: NCT00091858).
- 16 Nov 2006 Planned patient number is 1000 according to ClinicalTrials.gov (Parent trial: NCT00091858).